ASLN ASLAN Pharmaceuticals Limited

0.67
-1.41  -68%
Previous Close 2.08
Open 1.49
Price To Book 1.62
Market Cap 21,345,159
Shares 32,049,788
Volume 418,415
Short Ratio
Av. Daily Volume 20,769
Stock charts supplied by TradingView

NewsSee all news

  1. ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

    - The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control arm. These were not

  2. ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended

  3. ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

    - Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability profile, complete

  4. ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility

    SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3 million loan

  5. New Data Presented on ASLAN's varlitinib at ESMO 2019

    SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced  the presentation of new data from a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint - November 11, 2019.
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Varlitinib
Gastric cancer
Evaluating next steps - noted August 2019.
ASLAN003
Acute Myeloid Leukemia (AML)
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer
Phase 1 interim data due early 2020.
ASLAN004
Atopic dermatitis
Phase 1 presentation at ESMO September 28, 2019.
Varlitinib + mFOLFIRI
Solid tumors

Latest News

  1. ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

    - The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control arm. These were not

  2. ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended

  3. ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

    - Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability profile, complete

  4. ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility

    SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3 million loan

  5. New Data Presented on ASLAN's varlitinib at ESMO 2019

    SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced  the presentation of new data from a

  6. ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

    - ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million  - ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR

  7. ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

    - Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months - Patients

  8. Abstract on ASLAN Pharmaceuticals' Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

    SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate,

  9. New Data From Aslan's Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

    SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking abstract detailing